ATRA

Atara Biotherapeutics (ATRA)

About Atara Biotherapeutics (ATRA)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Details

Daily high

$6.94

Daily low

$6.44

Price at open

$6.50

52 Week High

$18.70

52 Week Low

$5.00

Market cap

38.6M

Dividend yield

0.00%

Volume

94,209

Avg. volume

48,486

P/E ratio

-.50

Atara Biotherapeutics News